Staar Surgical (STAA) earnings call transcripts

Management framed the quarter as evidence that China share gains, U.S. momentum and improved execution can support growth while the company rebuilds its innovation pipeline.

Management framed Q1 as evidence that 2025 disruptions have largely cleared, while withholding full-year guidance until demand visibility improves.

Management framed the quarter as share gains and execution against a declining refractive market, while tempering near-term expectations for macro and geopolitical uncertainty. 93 U.S.

Management framed 2023 as a year of execution, tempering near-term expectations while emphasizing APAC strength and longer-term U.S. adoption potential. U.S.

Management framed the quarter as broad-based ICL share gains despite weak refractive markets, with China recovered and U.S. launch investments still building adoption.

Management framed 2023 as an investment year, with confidence in China’s recovery and a sharper push to build U.S. EVO adoption. $5 million of Q4 sales were removed amid China’s COVID-related disruption.

Management framed the reset as temporary China demand deferral and currency pressure, while shifting resources toward EVO and signaling stronger U.S. momentum.

Management framed growth as broad-based EVO adoption overcoming currency and COVID disruptions, while stressing U.S. launch investment and refusing to quantify U.S. growth.

Management framed the quarter around strong global ICL demand and a newly opened U.S. growth opportunity, while highlighting China lockdowns and launch spending timing. 600 U.S.

Management framed 2022 as a capacity-building and brand-investment year, with non-U.S. markets leading growth while U.S. approval remains uncertain.

Management framed demand as accelerating beyond available production, while portraying the supply shortfall as temporary and U.S. approval as the remaining major catalyst.